Moleculin Biotech, Inc. (MBRX)
NASDAQ: MBRX · Real-Time Price · USD
0.3220
+0.0274 (9.30%)
At close: Jun 26, 2025, 4:00 PM
0.3070
-0.0150 (-4.66%)
After-hours: Jun 26, 2025, 7:59 PM EDT
Moleculin Biotech Stock Forecast
MBRX's stock price has decreased by -90.84% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 3 analysts that cover Moleculin Biotech stock have a consensus rating of "Strong Buy" and an average price target of $5.33, which forecasts a 1555.28% increase in the stock price over the next year. The lowest target is $4 and the highest is $8.
Price Target: $5.33 (+1555.28%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Moleculin Biotech stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $4 | Strong Buy | Reiterates | $4 | +1,142.24% | Jun 18, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $4 | Strong Buy | Initiates | $4 | +1,142.24% | Jun 9, 2025 |
| Maxim Group | Maxim Group | Hold → Strong Buy Upgrades $4 | Hold → Strong Buy | Upgrades | $4 | +1,142.24% | Mar 25, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $8 | Strong Buy | Reiterates | $8 | +2,384.47% | Mar 25, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $8 | Strong Buy | Reiterates | $8 | +2,384.47% | Mar 24, 2025 |
Financial Forecast
Revenue This Year
n/a
from 74.14M
Revenue Next Year
n/a
EPS This Year
-1.71
from -6.32
EPS Next Year
-1.47
from -1.71
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | n/a | n/a | ||
| Avg | n/a | n/a | n/a | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.43 | -1.42 | -1.38 | ||
| Avg | -1.71 | -1.47 | -1.40 | ||
| Low | -1.98 | -1.47 | -1.41 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.